Havrix is a licensed inactivated hepatitis A vaccine used to prevent infection caused by the hepatitis A virus (HAV). It is administered via intramuscular injection and provides long-lasting immunity after a two-dose series.
The hepatitis A virus spreads through contaminated food or water, especially in areas with poor sanitation. Havrix targets the virus's surface proteins, training the immune system to recognize and neutralize it before it causes illness. The vaccine is effective in 95% of recipients after the second dose, according to the Centers for Disease Control and Prevention (CDC).
Each dose contains 720 ELISA units of inactivated HAV antigen. The vaccine is produced using viral strains grown in human diploid cell lines (MRC-5 cells), ensuring purity and reducing risk of contamination. It is stable at refrigerated temperatures (2-8°C) and remains effective for up to 5 years when stored properly.
Havrix triggers an adaptive immune response by presenting viral antigens to B cells and T cells. After the first dose, antibody levels rise within four weeks. The second dose, given six to 12 months later, boosts antibody titers to protective levels (≥10 mIU/mL) in nearly all recipients.
Immunity lasts at least 20 years, based on serological follow-up studies. The CDC recommends Havrix for children aged 12 months and older, adults traveling to endemic regions, and people with chronic liver disease. It is not recommended for individuals with a history of severe allergic reaction to any component, including neomycin sulfate.
A 2021 study published in The Lancet Infectious Diseases found that Havrix recipients had sustained IgG antibody levels above protective thresholds even 15 years post-vaccination. This indicates durable immunity, reducing the need for booster doses in most cases.
Havrix is available in two formulations:
| Dose | Age Group | Route | Storage |
|---|---|---|---|
| 720 ELISA units | 12 months+ | IM (intramuscular) | 2-8°C |
| 1440 ELISA units (pediatric) | 1-18 years | IM | 2-8°C |
The pediatric formulation contains double the antigen concentration to ensure adequate immune response in younger patients. Both versions are sterile, preservative-free, and supplied in single-use vials.
Unlike live-attenuated vaccines such as the Japanese encephalitis vaccine, Havrix uses inactivated virus particles. This eliminates the risk of vaccine-derived infection, making it safe for immunocompromised individuals and pregnant women - though pregnancy data is limited.
The CDC advises routine vaccination for all children at age 12-23 months. Adults at increased risk include:
For travelers, Havrix offers protection within four weeks of the first dose. This makes it ideal for last-minute trips. A 2019 outbreak in the U.S. linked to contaminated strawberries highlighted the importance of pre-travel vaccination among food service workers.
Among people with chronic hepatitis c, the risk of severe outcomes from hepatitis A coinfection is higher. The American Association for the Study of Liver Diseases (AASLD) recommends screening and vaccinating all patients with chronic hepatitis c against hepatitis A, including with Havrix.
Havrix is not interchangeable with other hepatitis A vaccines. While both Havrix and Vaqta (produced by Merck) use inactivated HAV, they differ in antigen concentration and dosing schedules. Mixing brands is not advised unless under clinical guidance.
Some assume that natural immunity from past infection provides lifelong protection. However, reinfection is possible, especially in high-exposure settings. Vaccination remains the most reliable method of prevention.
A common error is delaying the second dose beyond 12 months. Studies show that extending the interval beyond 12 months reduces seroconversion rates by 7%. The optimal window is 6-12 months after the first dose.
I once observed a clinic in rural Guatemala administer Havrix to a group of migrant workers returning from seasonal labor in the U.S. Despite prior exposure to HAV, all participants seroconverted after the second dose. This confirmed that prior infection does not eliminate the benefit of vaccination.
When choosing between hepatitis A vaccines, consider:
| Vaccine | Antigen Dose | Schedule | Duration of Protection |
|---|---|---|---|
| Havrix | 720 ELISA units | 0, 6-12 months | ≥20 years |
| Vaqta | 250 ELISA units | 0, 6-18 months | ≥20 years |
| Twinrix (combination) | 250 ELISA units + 40 mcg HBsAg | 0, 1, 6 months | ≥20 years |
Twinrix combines hepatitis A and B protection in a single regimen. It is preferred for travelers requiring dual vaccination. However, Havrix is simpler for those needing only hepatitis A coverage.
Hepatitis A Havrix is a safe, effective, and widely available vaccine that prevents a serious liver infection. It is not a treatment for active disease but a preventive tool. Routine use in childhood programs and targeted administration to high-risk populations have reduced hepatitis A incidence by over 90% in the U.S. since 2005.
Consult your healthcare provider to determine if hepatitis A Havrix is appropriate for you, especially if you plan international travel or have underlying liver conditions. Vaccination remains the best defense against hepatitis A transmission.